Biotech entity
gene-therapy is the sole category represented across all 2 tracked stories. Casgevy is most often covered alongside CRISPR Therapeutics, which appears in 2 of these 2 stories. They are better corroborated than the beat average, carrying 11 original sources each against 3.6 for the same window.
Last mentioned: Sep 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 2 tracked stories. Casgevy is most often covered alongside CRISPR Therapeutics, which appears in 2 of these 2 stories. They are better corroborated than the beat average, carrying 11 original sources each against 3.6 for the same window. Across a 57-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6.5 runs above the beat's 6 for that window. This profile follows 2 Biotech stories mentioning Casgevy across the period from July 9, 2026 to September 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 259 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Casgevy. Shared-story counts are live from our verified record — not editorial picks.
Label expansion
FDA expands Casgevy’s indication to include patients as young as two years old, enabling earlier intervention.
Casgevy approval
FDA approves Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older.
The Casgevy label expansion to ages 2+ broadens the patient pool for the first approved CRISPR therapy. Upcoming clinical readouts may de-risk CRISPR Therapeutics' gene-editing platform beyond rare hemoglobinopathies.
Source: The Motley Fool · Prosper Junior Bakiny (us)
The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Source: wdov.iheart.com · kogo.iheart.com
Casgevy is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
